Hypothermia does not improve result in patients with severe bacterial meningitis

NewsGuard 100/100 Score

Bruno Mourvillier, M.D., of the Université Paris Diderot, Sorbonne Paris Cité, Paris, and colleagues conducted a study to examine whether treatment with hypothermia would improve the functional outcome of comatose patients with bacterial meningitis compared with standard care.

Among adults with bacterial meningitis, the death rate and frequency of neurologic complications are high, indicating the need for new therapeutic approaches. Clinical trials of patients with trauma who were treated with hypothermia have shown a decrease of intracranial pressure, suggesting a potential benefit of this technique in bacterial meningitis, according to background information in the article appearing in JAMA.

The randomized trial conducted in 49 intensive care units in France between February 2009 and November 2011 assessed 130 patients for eligibility and randomized 98 comatose adults with community acquired bacterial meningitis to the hypothermia group, where patients received a loading dose of 39°F cold saline and were cooled to 90°F to 93°F for 48 hours, or standard care.

The trial was stopped early because of concerns over excess mortality in the hypothermia group (25 of 49 patients [51 percent]) compared with the control group (15 of 49 patients [31 percent]). At 3 months, 86 percent in the hypothermia group compared with 74 percent in the control group had an unfavorable outcome (as gauged via the Glasgow Outcome Scale [a functional assessment inventory]).

"In conclusion, our trial does not support the use of hypothermia in adults with severe meningitis. Moderate hypothermia did not improve outcome in patients with severe bacterial meningitis and may even be harmful. Our results may have important implications for future trials on hypothermia in patients presenting with septic shock or stroke. Careful evaluation of safety issues in these future and ongoing trials are needed," the authors write.

Source:

Université Paris Diderot

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New treatments in sight for challenging neuropsychiatric symptoms in neurodegenerative diseases